WATCH | #Aids2020 study: Dolutegravir doesn't pose a higher risk for birth defects. Here's why.

Last year, South Africa launched a new HIV treatment, called dolutegravir. 

Back then, research indicated that the pill could be linked to an increased risk of defects in babies’ brains if women fell pregnant while using it. Or, if they were taking dolutegravir during the early stages of pregnancy. 

Now, new research has found that, in fact, birth defects are no more likely when pregnant women are taking dolutegravir than with other antiretrovirals. 

*This video was produced by the Bhekisisa Centre for Health Journalism. Sign up for the newsletter.

Image credit: Baz Ratner

We live in a world where facts and fiction get blurred
In times of uncertainty you need journalism you can trust. For only R75 per month, you have access to a world of in-depth analyses, investigative journalism, top opinions and a range of features. Journalism strengthens democracy. Invest in the future today.
Subscribe to News24
Voting Booth
Have you entered our Health of the Nation survey?
Please select an option Oops! Something went wrong, please try again later.
Results
Yes
34% - 9250 votes
No
66% - 17780 votes
Vote